Erlotinib Tablets: 5 FAQs About Uses, Dosage, Side Effects
Comprehensive guide to Erlotinib (Tarceva) for NSCLC and pancreatic cancer treatment, dosage, side effects, and patient advice.
About Erlotinib Tablets
Erlotinib, marketed as Tarceva, is a targeted anticancer medication belonging to the class of tyrosine kinase inhibitors. It specifically targets the epidermal growth factor receptor (EGFR), a protein that promotes uncontrolled cell growth in certain cancers. By reversibly binding to the EGFR tyrosine kinase at the ATP-binding site, erlotinib inhibits signal transduction pathways, preventing cancer cell proliferation and survival.
This drug is primarily indicated for non-small cell lung cancer (NSCLC) and pancreatic cancer. In NSCLC, it is used for patients with specific EGFR mutations, such as exon 19 deletions or exon 21 (L858R) substitutions, confirmed by FDA-approved tests. For pancreatic cancer, it is combined with gemcitabine.
What is Erlotinib used for?
Erlotinib is FDA-approved for the following indications:
- Non-Small Cell Lung Cancer (NSCLC): Maintenance treatment in patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. It is also used as monotherapy after failure of at least one prior chemotherapy regimen, particularly in tumors with EGFR exon 19 deletions or exon 21 L858R mutations.
- Pancreatic Cancer: First-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer in combination with gemcitabine.
Clinical trials, including two multicenter, placebo-controlled Phase 3 studies, demonstrated improved survival in NSCLC patients treated with erlotinib compared to placebo.
Before taking Erlotinib
Allergy and Medical History
Do not take erlotinib if you are allergic to it or any ingredients in Tarceva. Inform your doctor about any history of lung disease (e.g., interstitial lung disease, ILD), liver problems, kidney issues, gastrointestinal disorders, or bleeding tendencies, as these may affect suitability.
Pregnancy and Breastfeeding
Erlotinib can harm the unborn baby. Women should use effective contraception during treatment and for at least 2 weeks after the last dose. Men should use contraception during treatment and up to 4 weeks post-treatment. It is unknown if erlotinib passes into breast milk; breastfeeding should be avoided during treatment and for 2 weeks after.
Testing Requirements
For NSCLC, an FDA-approved test must confirm EGFR mutation presence before starting therapy.
How and when to take Erlotinib
Dosage
The recommended daily dose for NSCLC is 150 mg taken orally once daily. For pancreatic cancer, it is 100 mg daily in combination with gemcitabine (1000 mg/m² on days 1, 8, and 15 of a 28-day cycle).
| Indication | Recommended Dose | Administration |
|---|---|---|
| NSCLC (Maintenance or Second-line) | 150 mg once daily | On empty stomach |
| Pancreatic Cancer (with gemcitabine) | 100 mg once daily | On empty stomach; 1 hour before or 2 hours after food |
Administration Instructions
- Swallow tablets whole with a full glass of water.
- Take at least one hour before or two hours after food to ensure optimal absorption.
- If vomiting occurs after dosing, do not take an extra dose; skip and resume the next day.
- Missed dose: Take as soon as remembered unless close to next dose; do not double up.
Dose Adjustments
Reduce dose by 50 mg increments for intolerable side effects like severe rash, diarrhea, or liver dysfunction. Interrupt for ILD, severe hepatic impairment (bilirubin >3x ULN or transaminases >5x ULN), or persistent severe symptoms. Discontinue permanently for confirmed ILD, severe skin reactions (e.g., SJS/TEN), or GI perforation.
For patients with hepatic impairment, monitor liver function tests (transaminases, bilirubin, alkaline phosphatase) periodically. No specific adjustments for renal impairment unless severe.
Common questions about Erlotinib
- How long does it take to work? Response varies; some patients see benefits within weeks, but full effects may take months. Regular scans monitor progress.
- Will I gain weight? Weight loss is more common due to diarrhea or reduced appetite, not gain.
- Can I drive while taking it? Yes, unless side effects like fatigue or vision changes impair ability.
- Is it a chemo drug? No, it’s targeted therapy, not traditional chemotherapy.
Side effects of Erlotinib
Erlotinib commonly causes skin rash (up to 75% of patients), diarrhea (50-60%), fatigue, anorexia, and dry skin. Rash typically appears within 1-2 weeks.
Serious side effects
- Interstitial Lung Disease (ILD): Rare (1-2%) but fatal; symptoms include dyspnea, cough, fever. Discontinue immediately if suspected.
- Hepatotoxicity: Monitor LFTs; interrupt if transaminases >3x ULN with bilirubin >2x ULN.
- Gastrointestinal Perforation: Risk increased with NSAIDs, steroids; symptoms: abdominal pain, bleeding.
- Skin Reactions: Severe rash, bullous lesions; hold dose and consider antibiotics.
- Ocular Disorders: Keratitis, dry eyes; use artificial tears.
- Cerebrovascular Events: Rare reports of stroke.
Managing side effects
| Side Effect | Management |
|---|---|
| Rash/Dry Skin | Moisturizers, avoid sun, topical steroids if severe. Antibiotics for infection. |
| Diarrhea | Loperamide; hydrate; dose reduce if persistent. |
| Fatigue | Rest, balanced diet, light exercise. |
| Liver Issues | Regular blood tests; avoid alcohol. |
In NSCLC trials, rash led to dose reduction/interruption in 5.1% and discontinuation in some cases.
How to cope with side effects of Erlotinib
- Rash: Use alcohol-free skincare, sunscreen (SPF 30+), avoid hot showers. Consult dermatologist for severe cases.
- Diarrhea: Eat bland foods, stay hydrated, use OTC anti-diarrheals as directed.
- Mouth Sores: Saltwater rinses, soft foods.
- Nail Changes: Keep nails short, moisturize cuticles.
- Report fever >100.5°F, severe symptoms immediately.
Pregnancy and breastfeeding with Erlotinib
Category D: Avoid in pregnancy due to fetal harm risk. Use contraception as noted. Breastfeeding contraindicated.
Other medicines, food and drink, alcohol with Erlotinib
Drug Interactions
Strong CYP3A4 Inhibitors (e.g., ketoconazole): Reduce erlotinib dose by 50 mg. Inducers (e.g., rifampin): Avoid or increase dose to 300 mg.
Antacids/Proton Pump Inhibitors: Separate by 4+ hours; may reduce efficacy.
Avoid smoking: Reduces exposure by 50-60%; counsel cessation.
Warfarin: Monitor INR; increased bleeding risk.
Food and Alcohol
Take on empty stomach. Grapefruit may increase levels. Limit alcohol to avoid liver strain.
Cautions when taking Erlotinib
- Monitor for ILD, especially with prior lung issues.
- Regular LFTs and eye exams.
- Avoid sun exposure; use protective clothing.
Information for patients
Attend all appointments for blood tests and scans. Report new symptoms promptly. Maintain oral hygiene. A healthy diet supports treatment tolerance.
Frequently Asked Questions (FAQs)
Q: What is the main side effect of Tarceva?
A: The most common is an acne-like skin rash, affecting most patients within the first two weeks.
Q: Can Erlotinib cure lung cancer?
A: It is not curative but can prolong survival and control advanced disease in eligible patients.
Q: How long do you take Tarceva?
A: Continuously as long as it benefits and side effects are manageable, per doctor’s guidance.
Q: Does Tarceva cause hair loss?
A: Hair thinning may occur but is less severe than with chemotherapy.
Q: Is Erlotinib chemotherapy?
A: No, it’s a targeted oral therapy blocking specific cancer growth signals.
References
- Tarceva (erlotinib) Label — U.S. Food and Drug Administration (FDA). 2010-04. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf
- Erlotinib (oral route) – Side effects & dosage — Mayo Clinic. Accessed 2026. https://www.mayoclinic.org/drugs-supplements/erlotinib-oral-route/description/drg-20067325
- Erlotinib (Tarceva): Uses, Side Effects, Dosage & Reviews — GoodRx. Accessed 2026. https://www.goodrx.com/erlotinib/what-is
- Erlotinib: Uses, Interactions, Mechanism of Action — DrugBank. Accessed 2026. https://go.drugbank.com/drugs/DB00530
- Erlotinib (Tarceva®) — University of Pennsylvania Medical Center. Accessed 2026. https://www.med.upenn.edu/lung2022/assets/user-content/documents/erlotinib-tarceva-16105-14-eng-us.pdf
- Erlotinib (Tarceva) — Cancer Research UK. Accessed 2026. https://www.cancerresearchuk.org/about-cancer/treatment/drugs/erlotinib
- Erlotinib (Tarceva®) — Macmillan Cancer Support. Accessed 2026. https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/erlotinib
Similar Articles
Read full bio of Sneha Tete
